Scholar Rock's apitegromab faces Sept. 30 FDA decision on SMA muscle drug
The BLA rests on a Phase 3 trial the company says met its primary endpoint, with the September 30 PDUFA date now turning on manufacturing inspections rather than the clinical data.
Executive Summary
- Scholar Rock is awaiting an FDA decision on apitegromab, a myostatin-targeted antibody positioned as an add-on to existing SMA therapies, with the agency's action date now weeks away.
- The regulatory filing rests on a completed Phase 3 trial that enrolled patients already stable on background SMN-directed therapy, testing whether adding a muscle-directed antibody improves motor function beyond what those therapies achieve alone.
- The clearer near-term risk sits in manufacturing: a facility inspection has been completed and a compliance classification is due on a timeline that could land close to the decision date itself.
- No therapy sharing this drug's mechanism has reached FDA approval in this disease, so the field offers no same-target precedent for how the agency treats this evidence package.
The catalyst
The FDA accepted Scholar Rock's biologics license application for apitegromab and set a PDUFA action date of September 30, 2026. The application covers later-onset SMA (Type 2 and Type 3) in patients already treated with nusinersen or risdiplam, the two approved SMN-upregulator therapies, and includes two fill-finish manufacturing facilities: Catalent Indiana and a second U.S.-based site. Scholar Rock's chairman and CEO, David Hallal, said the company's commercial team "stands ready to launch apitegromab on or at any time prior to the September 30th PDUFA date". ScholarScholar Rock Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial behind the filing
The BLA is built on SAPPHIRE (NCT05156320), a randomized, placebo-controlled Phase 3 trial that enrolled 188 patients across nine countries, with three experimental arms and two placebo-comparator arms. The primary endpoint measures change from baseline in the Hammersmith Functional Motor Scale Expanded (HFMSE) total score in the main efficacy population, a motor-function scale used to gauge whether add-on treatment produces gains beyond the background SMN therapy alone. The trial completed in December 2024 and moved to Completed status in March 2025. Scholar Rock describes apitegromab as the first muscle-targeted candidate in SMA "to demonstrate a statistically significant and clinically meaningful benefit in a pivotal Phase 3 clinical trial". NCT05156320+1Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamNCT05156320Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026
Manufacturing as the live variable
The FDA completed a reinspection of the Catalent Indiana facility after accepting the BLA, and facility classification is expected within 90 days of that reinspection under standard FDA practice. Commercial supply from the second fill-finish facility is expected to become available early in the third quarter of 2026. Both timelines sit close to the September 30 action date, making the manufacturing determination, not the clinical data, the variable most exposed to timing risk heading into the decision. ScholarScholar Rock Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026
Regulatory track and Europe
Apitegromab holds FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, along with EMA PRIME and Orphan Medicinal Product designations. A CHMP opinion on the European marketing application was anticipated near mid-2026, with Scholar Rock planning a European launch beginning in Germany in the second half of 2026. These designations reflect the rare-disease and unmet-need status of the program rather than a predictor of the FDA's ultimate action. ScholarScholar Rock Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026
Competitive and mechanistic context
Only two active industry trials study myostatin in SMA, and the target-indication pairing spans four trials and three sponsors with a maximum phase of Phase 3, indicating a sparsely populated mechanistic space. No myostatin-targeted therapy has recorded an FDA approval to date. The closest modality precedent is Scholar Rock's own earlier-stage apitegromab program in infants and toddlers (NCT07047144), rather than a competitor sharing the same target. The established standard of care in this population, SMN-directed therapies such as nusinersen and risdiplam, works through a different mechanism entirely, so apitegromab is positioned as an add-on rather than a replacement.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.